Skip to main content
OpenTrials
Completed

NCT Number: NCT05687539

Mastiha or Mastiha Water in Functional Dyspepsia

The main aim of this study is to establish whether Mastiha products ameliorate functional dyspepsia symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Andriana Kaliora

Athens, 17671, Greece

About this study

Functional dyspepsia has an approximate prevalence of 20% and is one of the main causes of upper abdominal discomfort. Its pathogenesis remain unclear and therapeutic options remain limited with patients seeking alternative therapies in herbal remedies. Mastiha has been proven to significantly improve symptoms in patients with functional dyspepsia compared to placebo. In the present study, the investigators aim to determine whether Mastiha capsules or Mastiha water have a better effect on the improvement of functional dyspepsia symptoms. Therefore, the investigators designed a randomized, three-way cross-over clinical trial. Fifty patients with functional dyspepsia, will be randomized over three treatment sequences of 30 days each, separated by 14-day washout periods. The three treatments will be: Mastiha capsules, Mastiha water or Mastiha free treatment. The primary outcome, which will be assessed by intention to treat, will be the Leuven Postprandial Distress Scale, a validated instrument for the assessment of symptoms in functional dyspepsia, supported by the European Medicines Agency.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

functional dyspepsia diagnosis according to

  • Rome criteria
  • negative urea breath test for Helicobacter pylori
  • upper gastrointestinal tract endoscopy with biopsy

Exclusion criteria

  • organic diseases, such as peptic ulcer, gastrointestinal neoplasms, gastroesophageal reflux, irritable bowel syndrome
  • pregnancy or lactation
  • history of abdominal surgery or actinotherapy
  • mental illness
  • Severe impairment of heart, liver, or kidney function or respiratory function
  • Alcohol overuse

Treatment and study plan

Mastiha water

Dietary Supplement

10ml of mastiha water before every meal for one month

Mastiha capsules

Dietary Supplement

2x350mg mastiha capsules before every meal for one month

Primary outcomes

  1. Changes in Leuven Postprandial Distress Scale (LPDS)

    Time frame: 1 month

    The change in Leuven Postprandial Distress Scale will be evaluated at follow-up. LPDS minimum score is 0 and maximum 32. Higher scores mean a worse outcome.

Secondary outcomes

  1. Change in quality of life

    Time frame: 1 month

    Change in quality of life at follow-up as assessed via the EQ-5D-5L questionnaire. EQ-5D-5L has a scale from 0 to 100, with higher scores meaning better outcomes.

  2. Use of medicines

    Time frame: 1 month

    The percentage of patients that changed drug dose of medicines for functional dyspepsia will be evaluated at follow-up.

  3. Change in anxiety

    Time frame: 1 month

    Change in anxiety at follow-up as assessed via the GAD-7 ANXIETY questionnaire. GAD-7 ANXIETY has a scale from 0 to 21, with higher scores meaning worse outcomes.

Sponsors and collaborators

Lead sponsor

Harokopio University

Other

Registry information

Official study title

The Effect of Mastiha Products on Functional Dyspepsia. A Randomised Crossover Study.

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 18, 2023
Registry last updated
Jan 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.